Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T, Paech D, Weller J, Schäfer N, Tzaridis T, Duffy C, Nitsch L, Schneider M, Potthoff AL, Steinbach JP, Hau P, Schlegel U, Seidel C, Krex D, Grauer O, Goldbrunner R, Zeiner PS, Tabatabai G, Galldiks N, Stummer W, Hattingen E, Glas M, Radbruch A, Herrlinger U, Schaub C. Zeyen T, et al. Among authors: hau p. J Neurooncol. 2023 Sep;164(3):607-616. doi: 10.1007/s11060-023-04444-x. Epub 2023 Sep 20. J Neurooncol. 2023. PMID: 37728779 Free PMC article.
Benchmarking palliative care practices in neurooncology: a german perspective.
Lawson McLean AC, Lawson McLean A, Ernst T, Forster MT, Freyschlag C, Gempt J, Goldbrunner R, Grau S, Jungk C, van Oorschot B, Rosahl SK, Wedding U, Senft C, Kamp MA; German Consortium for Excellence in Neurooncology, Palliative Care (GCE-NPC). Lawson McLean AC, et al. J Neurooncol. 2024 Jun;168(2):333-343. doi: 10.1007/s11060-024-04674-7. Epub 2024 May 2. J Neurooncol. 2024. PMID: 38696050
Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06).
Maier SH, Schönecker S, Anagnostatou V, Garny S, Nitschmann A, Fleischmann DF, Büttner M, Kaul D, Imhoff D, Fokas E, Seidel C, Hau P, Kölbl O, Popp I, Grosu AL, Haussmann J, Budach W, Celik E, Kahl KH, Hoffmann E, Tabatabai G, Paulsen F, Holzgreve A, Albert NL, Mansmann U, Corradini S, Belka C, Niyazi M, Bodensohn R. Maier SH, et al. Among authors: hau p. Clin Transl Radiat Oncol. 2024 May 4;47:100790. doi: 10.1016/j.ctro.2024.100790. eCollection 2024 Jul. Clin Transl Radiat Oncol. 2024. PMID: 38765202 Free PMC article.
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop.
Penas-Prado M, Theeler BJ, Cordeiro B, Dunkel IJ, Hau P, Mahajan A, Robinson GW, Willmarth N, Aboud O, Aldape K, Butman JA, Gajjar A, Kelly W, Rao G, Raygada M, Siegel C, Romo CG, Armstrong TS, Gilbert MR; NCI-CONNECT Adult Medulloblastoma Workshop. Penas-Prado M, et al. Among authors: hau p. Neurooncol Adv. 2020 Aug 17;2(1):vdaa097. doi: 10.1093/noajnl/vdaa097. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33005896 Free PMC article. Review.
Initial Cancer Treatment in Certified Versus Non-Certified Hospitals.
Schmitt J, Klinkhammer-Schalke M, Bierbaum V, Gerken M, Bobeth C, Rößler M, Dröge P, Ruhnke T, Günster C, Kleihues-van Tol K, Schoffer O; WiZen Study Group. Schmitt J, et al. Dtsch Arztebl Int. 2023 Sep 29;120(39):647-654. doi: 10.3238/arztebl.m2023.0169. Dtsch Arztebl Int. 2023. PMID: 37583089 Free PMC article.
Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre.
Scheiter A, Hierl F, Lüke F, Keil F, Heudobler D, Einhell S, Klier-Richter M, Konstandin NP, Weber F, Scheiter A, Kandulski A, Schlosser S, Cosma LS, Tews H, Weiss ARR, Grube M, Bumes E, Hau P, Proescholdt M, Steger F, Troeger A, Haferkamp S, Reibenspies LE, Schnabel MJ, Schulz C, Drexler K, Hatzipanagiotou ME, Seitz S, Klinkhammer-Schalke M, Unberath P, Calvisi DF, Pukrop T, Dietmaier W, Evert M, Utpatel K. Scheiter A, et al. Among authors: hau p. Br J Cancer. 2023 Apr;128(6):1134-1147. doi: 10.1038/s41416-022-02120-x. Epub 2022 Dec 26. Br J Cancer. 2023. PMID: 36572733 Free PMC article.
Extracellular vesicles secreted by 3D tumor organoids are enriched for immune regulatory signaling biomolecules compared to conventional 2D glioblastoma cell systems.
Schuster M, Braun FK, Chiang DM, Ludwig C, Meng C, Grätz C, Kirchner B, Proescholdt M, Hau P, Steinlein OK, Pfaffl MW, Riemenschneider MJ, Reithmair M. Schuster M, et al. Among authors: hau p. Front Immunol. 2024 Apr 25;15:1388769. doi: 10.3389/fimmu.2024.1388769. eCollection 2024. Front Immunol. 2024. PMID: 38726003 Free PMC article.
Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers.
Wu M, Hau PM, Li L, Tsang CM, Yang Y, Taghbalout A, Chung GT, Hui SY, Tang WC, Jillette N, Zhu JJ, Lee HHY, Kong EL, Chan MSA, Chan JYK, Ma BBY, Chen MR, Lee C, To KF, Cheng AW, Lo KW. Wu M, et al. Among authors: hau pm. Nat Commun. 2024 May 3;15(1):3729. doi: 10.1038/s41467-024-48031-8. Nat Commun. 2024. PMID: 38702330 Free PMC article.
Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475].
Le Rhun E, Gorlia T, Felsberg J, Jongen J, Maurage CA, Ducray F, Gramatzki D, Hau P, Chinot OL, Preusser M, Cartalat S, Roth P, van den Bent M, Furtner J, Collienne M, Reifenberger G, Weller M. Le Rhun E, et al. Among authors: hau p. Eur J Cancer. 2024 Jun;204:114066. doi: 10.1016/j.ejca.2024.114066. Epub 2024 Apr 23. Eur J Cancer. 2024. PMID: 38658199 Free article. No abstract available.
218 results